To all our clients, partners, staff and friends:
We at Gold Partners are proud to announce the recent appointment of Larry Bell, M.D., as President, Regulatory, Quality, Safety and Risk Management Services. Larry joined our team at the beginning of January, 2009. With the addition of Dr. Bell to the management team, Gold Partners will be able to utilize Dr. Bell’s extensive drug development knowledge, as well as his practical and personal experiences in project lifecycle management, providing a unique force in developing pharmaceutical leadership.
It’s important for us to have a group that works well together and more importantly, likes to work together. Larry has been a leader in drug approval efforts at several major companies, and he knows how to develop and inspire a team. Gold Partners has worked with Larry, at many levels, over the past decade. With Dr. Bell on board we can more effectively develop a thorough assessment of clients’ goals combined with an understanding of the broader business needs to provide the best possible talent at the optimal time.
We believe that the synergies created by Dr. Bell’s knowledge of clinical and regulatory medical team requirements and his broad range of industry experience, combined with Gold Partners’ 20-plus years of successful clinical and regulatory search, affords a unique offering in the marketplace that will meet both the current and future needs of our corporate clients. We have the experience, insight, proven track record and now the advantage of Dr. Bell’s experience and underlying approach, which is aligned with our founding values.
By adding Dr. Bell to our team, Gold Partners can provide a broader and deeper array of services to move our clients’ businesses forward and also expand our scope towards a growth segment of the industry which is smaller to mid-sized biotech and pharmaceutical companies.
Strategic Opportunities – Gold Partners & Dr. Bell:
Sweeping industry trends have implications for the treatment of disease, the need for new medicines and the appropriate commercial development model for pharmaceutical companies. This fast-changing, turbulent environment demands that the industry alter it’s business approach to executive search. Understanding the converging trends can lead to better and faster placement of the right team at the right time. Changes to the current development and regulatory realities require companies to attract and assess talent in new and different ways. The knowledge Larry brings to the table is comprehensive:
- Understanding of the necessary efficiencies and functionality of drug/biotech processes
- Critical key strategic decision making in product and personnel lifecycle management
- Strong working knowledge and association with the FDA
- Networking and partnership connectivity
- Internal team building, team assessment capabilities
- Consultative, inclusive and personal communication style
About Dr. Bell:
Prior to his position at Gold Partners as President, Regulatory, Quality, Safety and Risk Management Services, Dr. Bell has held positions of increasing areas of responsibility within the pharmaceutical industry. Most recently, he was Global Head of Regulatory Affairs, Pharmacovigilance and Risk Management at GE HealthCare (GEHC), Medical Diagnostics. Previous executive experiences have included; Global Head and Sr. Vice President at Amgen, Inc. and Aventis Pharmaceuticals, Senior Director, Regulatory Affairs at Merck and Director, Clinical Research and Clinical Pharmacology at Bristol-Myers-Squibb Research Institute (BMSRI).
His areas of responsibility have included Global Head of Worldwide Regulatory Affairs, Global Safety, Epidemiology and Risk Management, QA & CMC, Medical Writing, Regulatory Intelligence, Labeling and Operations, Clinical Development and Clinical Pharmacology. He has also led successful product, departmental and company wide lifecycle management initiatives. Dr. Bell’s experience has successfully allowed for the management of departments of more than 600 people and budgets exceeding $100 million.
Larry has represented the industry as a RACC member for the Pharmaceutical Manufacturers Association, he has been involved in filing over 100 INDs and been responsible for over 20 approved NDAs/sNDAs.
Dr. Bell has earned licensure and certification in Texas, California and Minnesota. He is board certified in internal medicine, and has held academic teaching positions and was Director of the Heart Disease Prevention Clinic and Co-Director of the Lipid Research Laboratory at the University of Minnesota. Dr. Bell has been a member of numerous professional societies such as the Drug Information Association, American Society for Clinical Trials, American Association for Clinical Chemistry, Pharmaceutical Manufacturers Association, and the American Society of Parenteral & Enteral Nutrition. He is published in numerous leading medical journals such as AJCN, JAMA, Practical Cardiology and the Society for Clinical Trials. Dr. Bell received a Doctor of Medicine from the University of Texas Medical Branch, Galveston, Texas.
We are thrilled to have Dr. Bell on board! Please join us in welcoming Dr. Larry Bell into the Gold Partners family!
Kindest Regards,
Mark Gold
Larry Bell, MD
Bryan Shea